PFIZER INC.

AstraZeneca and Daiichi Sankyo's Dato-DXd received FDA Breakthrough Therapy designation for EGFRm NSCLC, based on phase II and III study data. They submitted a new BLA for accelerated approval in this indication and withdrew an earlier BLA for nonsquamous NSCLC. Dato-DXd is also under review for HR+ HER2- breast cancer, with regulatory applications ongoing globally.

Johnson & Johnson seeks approval for Darzalex to treat high-risk smoldering myeloma, with AQUILA trial showing reduced risk of disease progression. GSK's Blenrep, after withdrawal, shows improved survival in DREAMM-7 trial. Emerging efforts aim to ease conditioning for genetic treatments in sickle cell disease. Kura Oncology's menin inhibitor shows promising results in AML, facing competition from J&J and Syndax. Pfizer's Oxbryta withdrawal for sickle cell disease remains unexplained.

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

Ally Schott's early endometriosis diagnosis at 12 led to limited treatment options and self-taught research. Despite its prevalence affecting 10% of women globally, endometriosis remains underfunded and poorly understood, with only two new drugs approved in the U.S. for pain management in the past decade. Women's health research generally suffers from insufficient funding and information deficits, hindering drug development. Recent federal efforts, including a $100 million investment by the Biden administration, aim to address these gaps, but future priorities under a new administration remain uncertain.

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

AstraZeneca's Imfinzi sBLA for muscle-invasive bladder cancer (MIBC) receives FDA priority review, with decision expected Q2 2025. Based on phase III NIAGARA study, Imfinzi showed reduced risk of disease progression/recurrence and death in MIBC patients.

Stefano Romeo's research identifies two types of steatotic liver disease: one aggressive, affecting the liver, and another linked to cardio-renal-metabolic syndrome. Genetic tests reveal 27 new variants, enabling risk score determination for tailored treatments. Parallel studies using unsupervised clustering confirm these findings, advancing precision medicine.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

SkyQuest projects the cancer monoclonal antibodies market to reach USD 337.92 billion by 2031, with a CAGR of 18.4% (2024-2031). Factors driving growth include high cancer incidence, biotechnology advancements, and rising use of combination therapies and biosimilars. North America leads due to robust R&D investments, while blood cancer treatments dominate the market. Key players include AbbVie, Amgen, Merck, and Bristol-Myers Squibb.

Global Nanopharmaceuticals Market expected to grow from USD 7.5 Billion in 2023 to USD 259.2 Billion by 2032, driven by advantages like enhanced bioavailability, targeted delivery, and reduced side effects. North America leads with USD 25.3 Billion in 2023. Nanopharmaceuticals revolutionize drug delivery, addressing complex diseases and overcoming traditional therapy limitations.